1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update: A report from the American heart association. Circulation 131: e29–e322 (2014)
2. Lioyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation 121: 568–613 (2010)
3. Grundy SM. HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia. New Engl. J. Med. 319: 24–32 (1988)
4. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33: 1569–1582 (1992)
5. Hernandez F, Illnait J, Mas R, Castano G, Fernandez L, Gonzalez M, Cordovi N, Fernandez JC. Effects of policosanol on serum lipids and lipoproteins in healthy volunteers. Curr. Ther. Res. 51: 568–573 (1992)